Stage III Hodgkin's disease - long-term results following chemotherapy, radiotherapy and combined modality therapy

M. Brada, S. Ashley, J. Nicholls, E. Wist, M. Colman, T. J. McElwaim, P. Selby, M. J. Peckham, A. Horwich

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

215 patients with stage III Hodgkin's disease (HD) were treated at the Royal Marsden Hospital between 1963 and 1985 (median follow-up 9 years). The actuarial 5- and 10-year survival was 77 and 65%, respectively with 55 and 48 % 5 and 10 year disease-free survival. Of 13 variables tested, age was the only independent prognostic indicator for survival on multivariate analysis. Patients aged under 40, 40-59 and over 60 years had a 10-year survival of 76, 41 and 8%, respectively (p ≪ 0.001). Ninety-one patients were initially treated with combined chemotherapy and radiotherapy (combined modality therapy, CMT), 73 patients with radiotherapy (RT) and 51 patients with chemotherapy (CT) alone. Patients under 40 years treated with CMT achieved the best disease-free survival (10 year disease-free survival: CMT 68%; RT 38%; CT 45%). The observed survival advantage for CMT was not statistically significant. In patients aged > 40 there was no survival or disease-free survival advantage following CMT. Analysis of recurrence pattern confirmed that CMT improves initial disease control both at previously involved and uninvolved sites. Recurrences at previously uninvolved sites continued up to 6 years following CT, up to 8 years following CMT and up to 14 years after RT alone. These results indicate that only long-term follow-up gives the true picture of stage III HD.

Original languageEnglish (US)
Pages (from-to)185-198
Number of pages14
JournalRadiotherapy and Oncology
Volume14
Issue number3
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Combined Modality Therapy
Hodgkin Disease
Radiotherapy
Drug Therapy
Disease-Free Survival
Survival
Recurrence
Multivariate Analysis

Keywords

  • age
  • combined modality therapy
  • Hodgkin's disease
  • stage III

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Stage III Hodgkin's disease - long-term results following chemotherapy, radiotherapy and combined modality therapy. / Brada, M.; Ashley, S.; Nicholls, J.; Wist, E.; Colman, M.; McElwaim, T. J.; Selby, P.; Peckham, M. J.; Horwich, A.

In: Radiotherapy and Oncology, Vol. 14, No. 3, 1989, p. 185-198.

Research output: Contribution to journalArticle

Brada, M, Ashley, S, Nicholls, J, Wist, E, Colman, M, McElwaim, TJ, Selby, P, Peckham, MJ & Horwich, A 1989, 'Stage III Hodgkin's disease - long-term results following chemotherapy, radiotherapy and combined modality therapy', Radiotherapy and Oncology, vol. 14, no. 3, pp. 185-198. https://doi.org/10.1016/0167-8140(89)90166-7
Brada, M. ; Ashley, S. ; Nicholls, J. ; Wist, E. ; Colman, M. ; McElwaim, T. J. ; Selby, P. ; Peckham, M. J. ; Horwich, A. / Stage III Hodgkin's disease - long-term results following chemotherapy, radiotherapy and combined modality therapy. In: Radiotherapy and Oncology. 1989 ; Vol. 14, No. 3. pp. 185-198.
@article{48b9740e081b4a82a8345eadd9f8ae47,
title = "Stage III Hodgkin's disease - long-term results following chemotherapy, radiotherapy and combined modality therapy",
abstract = "215 patients with stage III Hodgkin's disease (HD) were treated at the Royal Marsden Hospital between 1963 and 1985 (median follow-up 9 years). The actuarial 5- and 10-year survival was 77 and 65{\%}, respectively with 55 and 48 {\%} 5 and 10 year disease-free survival. Of 13 variables tested, age was the only independent prognostic indicator for survival on multivariate analysis. Patients aged under 40, 40-59 and over 60 years had a 10-year survival of 76, 41 and 8{\%}, respectively (p ≪ 0.001). Ninety-one patients were initially treated with combined chemotherapy and radiotherapy (combined modality therapy, CMT), 73 patients with radiotherapy (RT) and 51 patients with chemotherapy (CT) alone. Patients under 40 years treated with CMT achieved the best disease-free survival (10 year disease-free survival: CMT 68{\%}; RT 38{\%}; CT 45{\%}). The observed survival advantage for CMT was not statistically significant. In patients aged > 40 there was no survival or disease-free survival advantage following CMT. Analysis of recurrence pattern confirmed that CMT improves initial disease control both at previously involved and uninvolved sites. Recurrences at previously uninvolved sites continued up to 6 years following CT, up to 8 years following CMT and up to 14 years after RT alone. These results indicate that only long-term follow-up gives the true picture of stage III HD.",
keywords = "age, combined modality therapy, Hodgkin's disease, stage III",
author = "M. Brada and S. Ashley and J. Nicholls and E. Wist and M. Colman and McElwaim, {T. J.} and P. Selby and Peckham, {M. J.} and A. Horwich",
year = "1989",
doi = "10.1016/0167-8140(89)90166-7",
language = "English (US)",
volume = "14",
pages = "185--198",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Stage III Hodgkin's disease - long-term results following chemotherapy, radiotherapy and combined modality therapy

AU - Brada, M.

AU - Ashley, S.

AU - Nicholls, J.

AU - Wist, E.

AU - Colman, M.

AU - McElwaim, T. J.

AU - Selby, P.

AU - Peckham, M. J.

AU - Horwich, A.

PY - 1989

Y1 - 1989

N2 - 215 patients with stage III Hodgkin's disease (HD) were treated at the Royal Marsden Hospital between 1963 and 1985 (median follow-up 9 years). The actuarial 5- and 10-year survival was 77 and 65%, respectively with 55 and 48 % 5 and 10 year disease-free survival. Of 13 variables tested, age was the only independent prognostic indicator for survival on multivariate analysis. Patients aged under 40, 40-59 and over 60 years had a 10-year survival of 76, 41 and 8%, respectively (p ≪ 0.001). Ninety-one patients were initially treated with combined chemotherapy and radiotherapy (combined modality therapy, CMT), 73 patients with radiotherapy (RT) and 51 patients with chemotherapy (CT) alone. Patients under 40 years treated with CMT achieved the best disease-free survival (10 year disease-free survival: CMT 68%; RT 38%; CT 45%). The observed survival advantage for CMT was not statistically significant. In patients aged > 40 there was no survival or disease-free survival advantage following CMT. Analysis of recurrence pattern confirmed that CMT improves initial disease control both at previously involved and uninvolved sites. Recurrences at previously uninvolved sites continued up to 6 years following CT, up to 8 years following CMT and up to 14 years after RT alone. These results indicate that only long-term follow-up gives the true picture of stage III HD.

AB - 215 patients with stage III Hodgkin's disease (HD) were treated at the Royal Marsden Hospital between 1963 and 1985 (median follow-up 9 years). The actuarial 5- and 10-year survival was 77 and 65%, respectively with 55 and 48 % 5 and 10 year disease-free survival. Of 13 variables tested, age was the only independent prognostic indicator for survival on multivariate analysis. Patients aged under 40, 40-59 and over 60 years had a 10-year survival of 76, 41 and 8%, respectively (p ≪ 0.001). Ninety-one patients were initially treated with combined chemotherapy and radiotherapy (combined modality therapy, CMT), 73 patients with radiotherapy (RT) and 51 patients with chemotherapy (CT) alone. Patients under 40 years treated with CMT achieved the best disease-free survival (10 year disease-free survival: CMT 68%; RT 38%; CT 45%). The observed survival advantage for CMT was not statistically significant. In patients aged > 40 there was no survival or disease-free survival advantage following CMT. Analysis of recurrence pattern confirmed that CMT improves initial disease control both at previously involved and uninvolved sites. Recurrences at previously uninvolved sites continued up to 6 years following CT, up to 8 years following CMT and up to 14 years after RT alone. These results indicate that only long-term follow-up gives the true picture of stage III HD.

KW - age

KW - combined modality therapy

KW - Hodgkin's disease

KW - stage III

UR - http://www.scopus.com/inward/record.url?scp=0024543830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024543830&partnerID=8YFLogxK

U2 - 10.1016/0167-8140(89)90166-7

DO - 10.1016/0167-8140(89)90166-7

M3 - Article

C2 - 2710949

AN - SCOPUS:0024543830

VL - 14

SP - 185

EP - 198

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -